Risk stratification in the patient with unstable angina or non ST elevation MI

Jump to navigation Jump to search

Percutaneous coronary intervention Microchapters

Home

Patient Information

Overview

Risk Stratification and Benefits of PCI

Preparation of the Patient for PCI

Equipment Used During PCI

Pharmacotherapy to Support PCI

Vascular Closure Devices

Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT

Post-PCI Management

Risk Reduction After PCI

Post-PCI follow up

Hybrid coronary revascularization

PCI approaches

PCI Complications

Factors Associated with Complications
Vessel Perforation
Dissection
Distal Embolization
No-reflow
Coronary Vasospasm
Abrupt Closure
Access Site Complications
Peri-procedure Bleeding
Restenosis
Renal Failure
Thrombocytopenia
Late Acquired Stent Malapposition
Loss of Side Branch
Multiple Complications

PCI in Specific Patients

Cardiogenic Shock
Left Main Coronary Artery Disease
Refractory Ventricular Arrhythmia
Severely Depressed Ventricular Function
Sole Remaining Conduit
Unprotected Left Main Patient
Adjuncts for High Risk PCI

PCI in Specific Lesion Types

Classification of the Lesion
The Calcified Lesion
The Ostial Lesion
The Angulated or Tortuous Lesion
The Bifurcation Lesion
The Long Lesion
The Bridge Lesion
Vasospasm
The Chronic Total Occlusion
The Left Internal Mammary Artery
Multivessel Disease
Distal Anastomotic Lesions
Left Main Intervention
The Thrombotic Lesion

Risk stratification in the patient with unstable angina or non ST elevation MI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Risk stratification in the patient with unstable angina or non ST elevation MI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Risk stratification in the patient with unstable angina or non ST elevation MI

CDC on Risk stratification in the patient with unstable angina or non ST elevation MI

Risk stratification in the patient with unstable angina or non ST elevation MI in the news

Blogs on Risk stratification in the patient with unstable angina or non ST elevation MI

Directions to Hospitals Treating Percutaneous coronary intervention

Risk calculators and risk factors for Risk stratification in the patient with unstable angina or non ST elevation MI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Definition

  • Unstable angina: acute ischemic symptoms, with or without EKG changes (ST depression/transient ST elevation/new T wave inversion), and absence of troponin or CK-MB elevation.
  • Non ST elevation MI: acute ischemic symptoms, with or without EKG changes (ST depression/transient ST elevation/new T wave inversion), and presence of troponin or CK-MB elevation.

Risk stratification in patient with UA/NSTEMI

  • The Thrombolysis in Myocardial Infarction (TIMI) risk score for UA/NSTEMI:
    • The TIMI risk score for STEMI was created from simple arithmetic sum of independent predictors of mortality weighted according to the adjusted odds ratios from logistic regression analysis.
    • The patient pool (n=1957) came from the TIMI 11B trial.
    • The TIMI risk score was subsequently validated using the unfractionated heparin group from the ESSENCE trial and the enoxaparin groups from both the TIMI 11B and the ESSENCE trials.
    • TIMI risk score of 0-2 = low risk, TIMI risk score of 3-4 = moderate risk, TIMI risk score of 5-7 = high risk.
  • ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:
    • The guideline defined high risk as elevated cardiac enzymes, ST segment depression, recurrent angina, hemodynamic instability, sustained VT/VF, history of DM, prior PCI in the past 6 months or CABG.

Early invasive strategy vs non-invasive strategy

  • TACTICS-TIMI 18: In patients with UA/NSTEMI who was treated with tirofiban, the use of early invasive strategy reduce the rate of the primary end point (death, non-fatal MI, and rehospitalization for ACS at 6 months) from 19.4% to 15.9%.

References


Template:WikiDoc Sources